The company behind popular weight-loss drugs failed to disclose even more money it paid to healthcare groups and patient organisations , a pharmaceutical watchdog has said. Novo Nordisk - which ...

Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Jan 28 (Reuters) - The U.S. FDA has approved Novo Nordisk's (NOVOb.CO), opens new tab Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today. The company’s shares closed yesterday at $81.10. Nedelcovych covers the Healthcare ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

although there is a good chance they will recover and still deliver strong returns to patient investors. But which one is likely to perform better than the other? Let's find out. Novo Nordisk has ...

Novo Nordisk's stock (NVO) rose more than 8% in Friday trading on news that the company's latest weight-loss product delivered favorable results. The new drug, amycretin, similar to the company's ...

A next-generation Novo Nordisk obesity drug designed to hit two targets has preliminary clinical data showing 22% weight loss, results that suggest the once-weekly injection could have an edge ...